QTTB insider filings

Q32 Bio Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-10-14. Screen QTTB transaction legs live →

Insider transaction summary — last 90 days

2026-08-23 to 2026-11-21, from the filings listed below: 6 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By insider — same window

Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

InsiderFilingsPurchases (P)Sales (S)Other legs
Morrison Jodie Pope — CEO, Director2—2 legs · 13,066 sh · $189,831—
Kalowski Lee — CFO and President2—2 legs · 5,273 sh · $76,600—
Violette Shelia M. — Chief Scientific Officer2—2 legs · 3,715 sh · $53,964—

Recent insider filings — Q32 Bio Inc.

FiledFormInsiderReported transactionsSource
2026-10-144Kalowski Lee — CFO and PresidentSale (S): 1,301 @ $8.32EDGAR
2026-10-144Violette Shelia M. — Chief Scientific OfficerSale (S): 917 @ $8.32EDGAR
2026-10-144Morrison Jodie Pope — CEO, DirectorSale (S): 3,221 @ $8.32EDGAR
2026-08-274Violette Shelia M. — Chief Scientific OfficerSale (S): 2,798 @ $16.56EDGAR
2026-08-274Kalowski Lee — CFO and PresidentSale (S): 3,972 @ $16.56EDGAR
2026-08-274Morrison Jodie Pope — CEO, DirectorSale (S): 9,845 @ $16.56EDGAR
2026-07-214/ALundberg Sven Ante — DirectorGrant/award (A): 10,826 (derivative) @ $0EDGAR
2026-07-214/AXu Diyong — Director, 10% ownerGrant/award (A): 10,826 (derivative) @ $0EDGAR
2026-07-214/AGRAYZEL DAVID S. — DirectorGrant/award (A): 10,826 (derivative) @ $0EDGAR
2026-07-214/AManke Isaac — DirectorGrant/award (A): 10,826 (derivative) @ $0EDGAR
2026-07-214/ATZIANABOS ARTHUR — DirectorGrant/award (A): 10,826 (derivative) @ $0EDGAR
2026-07-214/AIwicki Mark T — DirectorGrant/award (A): 10,826 (derivative) @ $0EDGAR
2026-07-214/AThistle Mary — DirectorGrant/award (A): 10,826 (derivative) @ $0EDGAR
2026-07-214/ALAPORTE KATHLEEN — DirectorGrant/award (A): 10,826 (derivative) @ $0EDGAR
2026-07-204Violette Shelia M. — Chief Scientific OfficerGrant/award (A): 37,500 @ $0EDGAR
2026-07-204Kalowski Lee — CFO and PresidentGrant/award (A): 53,250 @ $0EDGAR
2026-07-204Morrison Jodie Pope — CEO, DirectorGrant/award (A): 132,000 @ $0EDGAR
2026-07-024Manke Isaac — DirectorOption exercise (M): 53,521 @ $2.80 · Option exercise (M): 53,521 (derivative) @ $0EDGAR
2026-06-164GRAYZEL DAVID S. — DirectorGrant/award (A): 9,810 (derivative) @ $0EDGAR
2026-06-164Xu Diyong — Director, 10% ownerGrant/award (A): 9,810 (derivative) @ $0EDGAR
2026-06-164Lundberg Sven Ante — DirectorGrant/award (A): 9,810 (derivative) @ $0EDGAR
2026-06-164Manke Isaac — DirectorGrant/award (A): 9,810 (derivative) @ $0EDGAR
2026-06-164TZIANABOS ARTHUR — DirectorGrant/award (A): 9,810 (derivative) @ $0EDGAR
2026-06-164Iwicki Mark T — DirectorGrant/award (A): 9,810 (derivative) @ $0EDGAR
2026-06-164Thistle Mary — DirectorGrant/award (A): 9,810 (derivative) @ $0EDGAR
2026-06-164LAPORTE KATHLEEN — DirectorGrant/award (A): 9,810 (derivative) @ $0EDGAR
2026-06-014Xu Diyong — Director, 10% ownerPurchase (P): 1,250,000 @ $8 · Purchase (P): 625,000 @ $8EDGAR
2026-06-014ORBIMED ADVISORS LLC — Director, 10% owner
OrbiMed Capital GP VII LLC — Director, 10% owner
OrbiMed Genesis GP LLC — Director, 10% owner
Purchase (P): 1,250,000 @ $8 · Purchase (P): 625,000 @ $8EDGAR
2026-03-204Violette Shelia M. — Chief Scientific OfficerGrant/award (A): 37,500 @ $0EDGAR
2026-03-204Kalowski Lee — CFO and PresidentGrant/award (A): 53,250 @ $0EDGAR
2026-03-204Morrison Jodie Pope — CEO, DirectorGrant/award (A): 132,000 @ $0EDGAR
2026-02-274Violette Shelia M. — Chief Scientific OfficerSale (S): 2,815 @ $4.51EDGAR
2026-02-274Kalowski Lee — CFO and PresidentSale (S): 3,995 @ $4.51EDGAR
2026-02-274Morrison Jodie Pope — CEO, DirectorSale (S): 9,896 @ $4.51EDGAR
2026-01-304GRAYZEL DAVID S. — DirectorGrant/award (A): 16,363 (derivative) @ $2.75EDGAR
2026-01-304Lundberg Sven Ante — DirectorGrant/award (A): 20,363 (derivative) @ $2.75EDGAR
2026-01-304LAPORTE KATHLEEN — DirectorGrant/award (A): 23,272 (derivative) @ $2.75EDGAR
2025-12-044Kalowski Lee — CFO and PresidentSale (S): 9,072 @ $3.46EDGAR
2025-12-044Morrison Jodie Pope — CEO, DirectorSale (S): 22,506 @ $3.46EDGAR
2025-10-274Lundberg Sven Ante — DirectorGrant/award (A): 53,521 (derivative) @ $0EDGAR
2025-10-274Xu Diyong — DirectorGrant/award (A): 53,521 (derivative) @ $0EDGAR
2025-10-274GRAYZEL DAVID S. — DirectorGrant/award (A): 53,521 (derivative) @ $0EDGAR
2025-10-274Manke Isaac — DirectorGrant/award (A): 53,521 (derivative) @ $0EDGAR
2025-10-274TZIANABOS ARTHUR — DirectorGrant/award (A): 53,521 (derivative) @ $0EDGAR
2025-10-274Iwicki Mark T — DirectorGrant/award (A): 53,521 (derivative) @ $0EDGAR
2025-10-274Thistle Mary — DirectorGrant/award (A): 53,521 (derivative) @ $0EDGAR
2025-10-274LAPORTE KATHLEEN — DirectorGrant/award (A): 53,521 (derivative) @ $0EDGAR
2025-08-284Violette Shelia M. — Chief Scientific OfficerSale (S): 2,990 @ $1.80EDGAR
2025-08-284Kalowski Lee — CFO and PresidentSale (S): 4,240 @ $1.80EDGAR
2025-08-284Morrison Jodie Pope — CEO, DirectorSale (S): 10,494 @ $1.80EDGAR

Recent 8-K events — Q32 Bio Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-048-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-308-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-148-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-08-058-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-158-K1.01 — Entry into a Material Definitive Agreement
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-138-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-138-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-168-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-05-278-K1.01 — Entry into a Material Definitive Agreement
3.02 — Unregistered Sales of Equity Securities
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-058-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=QTTB returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs